Schering-Plough's second-quarter profit falls despite sales increase
This article was originally published in Scrip
Executive Summary
Schering-Plough's second-quarter pharmaceutical net sales were up by 47% to $3.7 billion, though group income was down by 19% to $436 million due largely to charges that the company incurred upon the cancellation of its development programme with Merck & Coon a Claritin/Singulair combination (Scrip Online, June 30th, 2008). Total group sales were up by 55% to $4.9 billion.